Outpatient Administration of Blinatumomab Infusion and Hematopoietic Stem Cell Transplantation as Treatment for Patients with Refractory Acute Lymphoblastic Leukemia in a Pediatric Oncologic Center in Mexico

Acute Lymphoblastic Leukemia (ALL) is the most common pediatric cancer and the most common subtype of pediatric leukemia, the high toxicity of chemotherapy, the relapse and refractory disease of many patients require the development of novel therapeutic approaches such as targeted immunotherapy in combination with Hematopoietic Stem Cell Transplantation (HSCT). These new therapeutic approaches must be taken in count to revolutionize the management of numerous ALL subtypes, improve treatment outcomes and maintain low toxicity without losing the effectiveness of the treatment. Our retrospective, longitudinal, observational, descriptive study evaluated a novel therapeutic approach in a Pediatric Oncologic Center in Mexico, the outpatient administration of blinatumomab infusion in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL). The study demonstrated that 100% of the patients went into remission after Blinatumomab infusion and there was no mortality associated.